DexCom (NASDAQ:DXCM) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of DexCom (NASDAQ:DXCM) from a hold rating to a buy rating in a research note published on Tuesday morning.

Several other equities analysts have also recently issued reports on the stock. JPMorgan Chase & Co. cut shares of DexCom from an overweight rating to a neutral rating and lowered their price objective for the stock from $145.00 to $75.00 in a research note on Friday, July 26th. Morgan Stanley cut their price objective on DexCom from $120.00 to $75.00 and set an equal weight rating for the company in a research report on Friday, July 26th. Robert W. Baird lifted their target price on DexCom from $80.00 to $82.00 and gave the stock a neutral rating in a report on Monday, August 5th. Piper Sandler reaffirmed an overweight rating and set a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. Finally, BTIG Research decreased their price target on DexCom from $156.00 to $120.00 and set a buy rating for the company in a research report on Friday, July 26th. Six investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of $112.25.

DexCom Stock Performance

DXCM opened at $67.29 on Tuesday. The business has a 50 day moving average price of $74.55 and a two-hundred day moving average price of $107.88. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The company has a market capitalization of $26.76 billion, a price-to-earnings ratio of 43.86, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company’s revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.34 earnings per share. Research analysts predict that DexCom will post 1.69 EPS for the current fiscal year.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the sale, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at $4,607,617.95. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,824 shares of company stock worth $126,390. 0.30% of the stock is owned by company insiders.

Institutional Trading of DexCom

Large investors have recently added to or reduced their stakes in the business. Gilbert & Cook Inc. lifted its position in shares of DexCom by 8.2% in the fourth quarter. Gilbert & Cook Inc. now owns 3,431 shares of the medical device company’s stock worth $426,000 after buying an additional 261 shares during the last quarter. 9258 Wealth Management LLC bought a new stake in DexCom during the fourth quarter worth approximately $286,000. Dynamic Technology Lab Private Ltd bought a new stake in DexCom during the fourth quarter worth approximately $284,000. Cambridge Investment Research Advisors Inc. grew its holdings in DexCom by 156.7% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 67,932 shares of the medical device company’s stock valued at $8,430,000 after purchasing an additional 41,469 shares during the last quarter. Finally, SageView Advisory Group LLC bought a new position in shares of DexCom in the fourth quarter valued at approximately $344,000. 97.75% of the stock is owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.